<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00816322</url>
  </required_header>
  <id_info>
    <org_study_id>DMR93-IRB-87</org_study_id>
    <nct_id>NCT00816322</nct_id>
  </id_info>
  <brief_title>The Effect of Fish Oil in Major Depressive Disorder</brief_title>
  <official_title>The Effect of Fish Oil in Major Depressive Disorder: a Double-blind Placebo-controlled Monotherapy Trail and a RCT for Recurrence Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Science Council, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The whole study was divided into two major parts: (A) the 12-week, double-blind, randomized
      controlled, parallel omega-3 fatty acid monotherapy study in 60 patients with mild to
      moderate major depressive disorder. (B) The double-blind, randomized controlled, parallel
      omega-3 fatty acid add-on prevention study in 60 patients with major depressive disorder in
      recovery status.

      The goals of this study were to examine the therapeutic and recurrence prevention effects of
      omega-3 fatty acids on major depressive disorder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HAMD</measure>
    <time_frame>W0 W2 W4 W8 W12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>BDI</measure>
    <time_frame>W0 W2 W4 W8 W12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>W0 W2 W4 W8 W12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>M0 M1 M2 M3 M4 M6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>omega-3 fatty acids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EPA 2.1 g/d+DHA 1.1 g/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>high oleic oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3 fatty acids</intervention_name>
    <description>EPA 2.1 g/d+DHA 1.1 g/d</description>
    <arm_group_label>omega-3 fatty acids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>high oleic oil</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. DSM-IV criteria for major depressive disorder.

          2. Age being age 18-65.

          3. Capacity and willingness to give written informed consent.

        Exclusion Criteria:

          1. Any major medical illnesses.

          2. A recent or past history of any Axis-I diagnoses besides major depressive disorder,
             including psychotic disorders; cognitively impaired mental disorders; impulse control
             disorders; substance use disorder or substance abuse (last 6 months prior to the
             studies); primary anxiety disorders, including post-traumatic stress disorder and
             panic disorder; and bipolar disorders; or Axis-II diagnoses, i.e. borderline and
             antisocial personality disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>China Medical University</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2008</study_first_submitted>
  <study_first_submitted_qc>December 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2009</study_first_posted>
  <last_update_submitted>April 13, 2015</last_update_submitted>
  <last_update_submitted_qc>April 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Science Council, Taiwan</investigator_affiliation>
    <investigator_full_name>Kuan-Pin</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

